and radiation delivery, consistent hearing preservation remains elusive. 2, 17 The tremendous heterogeneity in treatment protocols and discrepancies in outcome reporting make comparison difficult between observation, microsurgery, SRS, and stereotactic radiotherapy. The issue of long-term hearing follow-up may be particularly relevant because hearing deterioration appears to follow a protracted course compared with early fifth and seventh cranial nerve deficits, stroke, and hydrocephalus, for example. 8, 17 Nevertheless, studies following SRS reporting median audiometric follow-up data beyond 5 years are a rarity. 1 Herein, the authors present the long-term hearing outcomes of 44 patients with sporadic VS who had serviceable pretreatment hearing levels and whose disease was managed with low-dose (12-to 13-Gy marginal dose) SRS between 1997 and 2002. Time to nonserviceable hearing and statistical associations with hearing deterioration are reported.
Methods

Patient Selection, Clinical Features, and Outcomes
After institutional review board approval, a prospectively maintained clinical database including all patients who had undergone SRS for VS was retrospectively reviewed. Initial data collection included the following pre-and posttreatment characteristics: audiometric data (PTA, SDS, and AAO-HNS hearing classification); length of audiometric follow-up; SRS planning parameters; tumor characteristics (laterality, location [extent of internal auditory canal and CPA involvement], size, volume, macrocystic features, distance to fundus, and brainstem contact); NF2 status; history of prior tumor treatment; and basic demographic information (age and sex). Pretreatment tumor size, location, and hearing capacity were reported according to the 1995 AAO-HNS guidelines. 4 Patients with serviceable hearing (AAO-HNS Class A or B) prior to SRS who received low-dose (12-to 13-Gy marginal dose) SRS between 1997 and 2002 were identified. Preliminary exclusion criteria included nonserviceable pretreatment hearing (AAO-HNS Class C or D), inadequate or missing pretreatment audiometric data, NF2, history of prior tumor treatment, progressive tumor growth following SRS requiring salvage microsurgery, age < 18 years, or marginal treatment dose ≥ 14 Gy. All patients meeting the initial study criteria were asked to return to the authors' institution (for a remuneration of US $60) so that up-to-date audiometric performance data could be obtained. Only patients with ≥ 5 years of audiometric follow-up were included in final analysis.
The primary outcome evaluated was time to nonserviceable hearing, which was defined as AAO-HNS Class C or D. A secondary study aim was to quantify posttreatment PTA and SDS decline as a function of time. Ipsilateral PTA and SDS deterioration was adjusted using the contralateral untreated ear as a control to account for hearing loss that "naturally" occurred during the course of follow-up. That is, any degree of hearing loss detected in the untreated ear at a given time point was credited back to the treated ear because over a long duration of follow-up, all hearing loss in the ipsilateral ear cannot be attributed solely to the tumor or its treatment. Equations used to determine interaural correction are as follows: adjusted ipsilateral PTA at year x = ipsilateral PTA at year x -(contralateral PTA at year x -pretreatment contralateral PTA); and adjusted ipsilateral SDS at year x = ipsilateral SDS at year x + (pretreatment contralateral SDS -contralateral SDS at year x).
Radiosurgical Planning Strategy
All patients were evaluated prior to SRS by a neurosurgeon-neurotologist team, and a thorough pretreatment neurological examination with audiometric analysis was obtained. Radiosurgery was performed using a model B or C Gamma Unit (Elekta AB). A model G Leksell stereotactic head frame (Elekta) was applied after induction of local anesthesia. High-resolution spoiled gradient-recalled acquisition T1-weighted MRI studies with 1-mmthick, volumetrically acquired slices (28-60 images) were obtained on a 1.5-T scanner (GE Healthcare) to well encompass the tumor and surrounding pertinent anatomy. Images were exported to a computer workstation for dose planning performed using the Leksell GammaPlan software (Elekta). Cochlear dosimetry and conformity indices were obtained retrospectively. The cochlear dose was obtained as a single point at the cochlear modiolus by 2 independent observers and then averaged. Unfortunately, due to limitations of the various earlier versions of the GammaPlan software, retrospective volumetric analysis of the cochlear dose could not be performed. The conformality of the plan was determined using the Paddick conformity index.
14 Parameters including maximum and marginal tumor dose, volume treated, cochlear point dose at the modiolus, number of isocenters, and conformity index were recorded.
Statistical Methods
Continuous features were summarized with means ± SDs, medians, and ranges; categorical features were summarized with frequency counts and percentages. Time to nonserviceable hearing was estimated using the KaplanMeier method. Univariate and multivariate associations with time to nonserviceable hearing were evaluated using Cox proportional hazards regression models and summarized with HRs and 95% CIs. A multivariate model was developed using stepwise selection, with the p value for a feature to enter or leave the model set at 0.05. Statistical analyses were performed using the SAS software package (SAS Institute). All tests were 2-sided and p values < 0.05 were considered statistically significant.
Results
Between 1997 and 2002, 182 patients underwent SRS for VS at our institution. Of these, 56 patients met initial study criteria, whereas 126 required preliminary exclusion for one or more reasons ( 21 .4% of all patients who met the initial study criteria had insufficient audiometric follow-up data and were excluded from final analysis. Pretreatment hearing capacity, tumor characteristics, and SRS treatment parameters for the 44 included patients are summarized in Table 2 .
The median duration of audiometric follow-up was 9.3 years (mean 8.3 ± 3.5 years, range 5-14 years) and the median number of audiometric evaluations per patient following SRS was 3 (mean 3.5 ± 2.4, range 1-13). Thirty-six patients developed nonserviceable hearing at a mean of 4.2 ± 3.8 years following treatment (median 2.1 years, range 0.5-12.3 years). The median duration of follow-up for the 8 patients who maintained serviceable hearing at last evaluation was 9.4 years (mean 9. Fig. 1) . None of the patients demonstrated improvement in hearing levels following treatment.
Univariate associations with time to nonserviceable hearing are summarized in Table 3 . Pretreatment ipsilateral PTA, the pretreatment ipsilateral AAO-HNS hearing classifications, tumor size, and brainstem contact were statistically significantly associated with time to nonserviceable hearing on univariate analysis. Each 10-dB increase in pretreatment ipsilateral PTA was associated with a 2-fold increased risk of posttreatment nonserviceable hearing (HR 2.01; p < 0.001). Pretreatment ipsilateral AAO-HNS Class B hearing was associated with a 2.4-fold increased risk of nonserviceable hearing compared with pretreatment AAO-HNS Class A hearing (HR 2.43; p = 0.01 [ Fig. 2] ). Patients with CPA tumors > 1 cm were 3.4 times more likely to progress to nonserviceable hearing compared with patients with intracanalicular tumors (HR 3.40; p = 0.005). Finally, tumors in contact with the brainstem were associated with a 2.4-fold increased risk of nonserviceable hearing (HR 2.38; p = 0.011).
A multivariate model to predict time to nonserviceable hearing is summarized in Table 3 . Pretreatment ipsilateral PTA and tumor size were jointly statistically significantly associated with time to nonserviceable hearing. Each 10-dB increase in pretreatment ipsilateral PTA was associated with a 2-fold increased risk of nonserviceable hearing following SRS (HR 1.99; p < 0.001). After adjusting for pretreatment ipsilateral PTA, patients with CPA tumors > 1 cm in diameter were 3.3 times more likely to progress to nonserviceable hearing compared with patients with intracanalicular tumors (HR 3.34; p = 0.009 [ Fig. 3] ). There was not a statistically significant difference in time to nonserviceable hearing between patients with CPA tumors ≤ 1 cm in diameter and those with intracanalicular tumors (p = 0.88).
A summary of ipsilateral PTA and SDS decline over the course of audiometric follow-up is reported with and without interaural correction in Table 4 . Over 14 years, the mean unadjusted and adjusted PTA loss on the ipsilateral side was 42.1 and 33.6 dB, respectively. The average unadjusted and adjusted SDS decline on the ipsilateral side following SRS was 47.6% and 45.8%, respectively. The mean PTA and SDS loss in the contralateral untreated "control" ear over the course of follow-up was 8.5 dB and 1.8%, respectively.
Discussion
Since its inception in 1951, SRS has undergone tremendous refinement, and today is an established alternative to microsurgical resection for a variety of benign and malignant skull base tumors. Specific to VS, SRS offers comparable tumor control among small-to medium-sized VSs, with several studies demonstrating a favorable profile with respect to cranial nerve injury and neurological morbidity. 13, 15 In the early 1990s SRS treatment plans frequently implemented ≥ 14 Gy to the tumor margin, which was associated with a high rate of early posttreatment hearing deterioration. 3 Within the last 15 years reduced dose strategies have become increasingly used, with the aim of further minimizing cranial nerve morbidity. Concerns regarding inconsistent reporting of audiometric data and a shortage of studies reporting long-term followup have made the true rate of durable hearing preservation following SRS a major point of contention among treating physicians. 1 In 1997 our institution began using a reduced-dose (12-13 Gy to the margin) treatment protocol for VS. The current study presents our experience managing these tumors in patients with serviceable pretreatment hearing between 1997 and 2002, thereby permitting a potential follow-up period of at least 10 years for all study participants. Forty-four of 56 patients with serviceable pretreatment hearing had > 5 years of audiometric follow-up and were included in analysis. Overall, less than one-fourth of patients maintained AAO-HNS Class A or B hearing a decade after treatment. Our data demonstrate a very divergent pattern of hearing deterioration at the 2-year time point. The early "acute" phase (< 2 years post-SRS) was marked by rapid hearing decline in which approximately 40% of patients lost serviceable hearing. During this interval, the mean interaural corrected PTA and SDS decline was 19.2 dB and 26.5%, respectively. The second "delayed" phase demonstrated a more insidious decline during which an additional approximately 40% of patients progressed to nonserviceable levels over the course of 8 years. Notably, hearing loss during this period still occurred at a much more rapid pace than age-associated decline, as evidenced by much slower progression in the contralateral "control" ear. This pattern of loss has been demonstrated in several other studies with sufficient periods of follow-up. 8, 17 We believe this observation is very important because data from studies with inadequate follow-up may lead to the inaccurate assumption that hearing loss following SRS for VS is exclusively an early phenomenon that levels off after the first several years. Our observations show that hearing loss following SRS continues to decline even 10 years after treatment.
The rate of hearing preservation in the current study coincides closely with other reports when comparing similar post-SRS time points. In 2010 Yang et al. 24 published a systematic review of the literature evaluating hearing preservation following SRS for VS. Among 4234 patients with a mean follow-up of 44.4 months (median 35 months) the overall percent of patients with serviceable hearing was 51%. On dose-dependent subgroup analysis, 60.5% of patients receiving ≤ 13 Gy maintained serviceable hearing compared with 50.4% of patients receiving > 13 Gy. Hasegawa et al. 8 reported hearing outcomes at a median follow-up of 38 months among 117 patients treated with a mean marginal dose of 12.4 Gy. These investigators found an actuarial hearing preservation rate of 55% at 3 years and 34% at 8 years. Roos et al. 17 reported hearing preservation rates among 50 patients after treatment with linear accelerator-based SRS and found that the Kaplan-Meier estimated rate of useful hearing at 3 years was approximately 55%, but only 23% at 10 years. In their study, hearing preservation was defined as a PTA ≤ 50 dB, whereas SDS was not evaluated. In our study, 55% of patients maintained AAO-HNS Class A or B hearing at 3 years and 23% had serviceable hearing at 10 years.
The microsurgery literature demonstrates that among select tumors, serviceable hearing can be initially preserved in approximately 30%-60% of patients. 2, 6 In 2003 Chee and colleagues 2 reported their experience with longterm hearing preservation following retrosigmoid microsurgery, providing the longest published follow-up to date (mean 113.4 months). Of 126 patients, hearing preservation was successful in 43 (34.1%) immediately following surgery; 30 of the 43 eligible patients had follow-up > 36 months and were included in long-term analysis. These authors found that there was a highly statistically significant decline in SDS, PTA, and speech reception thresholds when comparing immediate postoperative audiometric data to those obtained at the last testing session; 35% of patients with initial Class A or B hearing progressed to nonserviceable hearing during follow-up. This means that < 25% of patients ultimately retained serviceable hearing approximately 10 years after microsurgical resection.
In 1990 Shelton et al. 18 reported the long-term audiometric outcomes (mean duration of follow-up 97.2 months) in 25 patients whose hearing was preserved early following middle fossa surgery. Similarly, they found a statistically significant decline in speech reception thresholds and SDS when comparing early postoperative hearing to last follow-up. They observed that 14 (56%) of 25 patients experienced significant hearing deterioration; this study was conducted prior to the 1995 AAO-HNS reporting guidelines, and "significant" hearing loss was defined by an SDS or PTA elevation of > 15 dB or an SDS loss of > 20%. Several other series have reported lesser degrees of hearing loss following successful hearing preservation microsurgery, but are limited by shorter durations of follow-up and a high percentage of patients who were lost to follow-up. 6, 23 Several authors have reported an increased probability of hearing preservation with "early proactive" treatment compared with observation. 12, 16 To date, the most robust natural history data comes from the Gentofte University Hospital in Copenhagen, Denmark. This single academic referral center evaluates all patients within the country of Denmark in whom VS is diagnosed, and has collected prospective clinical data for nearly 40 years in a captive population of approximately 5 million people. In 2006 these investigators found that in 729 patients allocated to a "watch-and-scan" strategy, only 17% of intracanalicular and 29% of cisternal tumors demonstrated growth on serial imaging. 19 In a follow-up study investigating long-term (mean follow-up 4.2 years; range 0.5-21 years) hearing preservation among 932 conservatively managed VSs, 70.1% of patients with Class A or B hearing at diagnosis maintained serviceable hearing at last evaluation. 20 Among patients with Class A hearing, 55% maintained Class A hearing at 5 years and 46% at 10 years following diag- nosis. The investigators also noted that in patients who had anything less than 100% SDS at presentation an accelerated rate of hearing loss in the first 2 years of observation could be predicted, followed by a more gradual decline thereafter. Although the degree of hearing loss was more significant among our cohort of patients whose tumors were managed with SRS, the patterns of loss were remarkably similar; an early precipitous loss followed by a gradual but persistent decline thereafter. Thus, some of the hearing loss observed following SRS may be due to the effects associated with tumors arising from the vestibulocochlear nerve, and not all of it directly due to adverse radiation effect. This may also explain why radiosurgical parameters such as cochlear dose are often not significant in predicting long-term hearing outcomes.
Régis et al. 16 found that when comparing upfront SRS to a "wait-and-see" strategy, patients were 20% more likely to retain useful hearing (Gardner-Robertson Class I or II) at the 4-and 5-year posttreatment time point. The median duration of follow-up in the observational study arm was 34.7 months, with 77% of tumors demonstrating growth. The rate of tumor growth in their series was more than double that reported by other larger observational studies. 20 Among 31 patients who presented with 12 reported their results in 162 consecutive patients undergoing a middle cranial fossa approach with at least 12 months of postoperative audiometric data available. They found that 22 (76%) of 29 patients presenting with small tumors (≤ 1 cm) and good preoperative hearing (> 70% word recognition scores) maintained > 70% word recognition scores at last follow-up. They concluded that early intervention for smaller VSs in patients with good pretreatment hearing may provide the best opportunity for hearing preservation. When compared with a much larger cohort of patients with conservatively managed tumors who had a similar audiometric starting point (> 70% SDS), at least 80% of patients maintained > 70% SDS at 1-2 years of observation.
Our data corroborate other studies demonstrating that if followed long enough, most patients with sporadic VS will ultimately develop nonserviceable ipsilateral hearing loss either as a result of treatment or from the natural course of disease; 3, 8, 17, 18 there is no contemporary treatment strategy that can reliably preserve long-term serviceable hearing in more than one-fourth of patients. The minority of patients with durable long-term hearing present with favorable features including small tumor size, fundal fluid capping (distancing the lateral tumor margin from the cochlea), and excellent pretreatment hearing; 8, 9, 11, 17, 22 these factors favorably influence outcome regardless of management strategy. 7, 12, 17, 20 There are several notable strengths of our study. We provide long-term audiometric follow-up in patients treated using reduced-dose planning, and results are presented according to standardized audiometric reporting guidelines. Additionally, we were able to maintain high cohort retention (79%) at a median of 9.3 years following treatment. Also, the data are presented using interaural audiometric correction to account for age-related hearing loss; this becomes increasingly important with longer periods of follow-up.
We wish to acknowledge several limitations as well. First, the Kaplan-Meier plot reporting time to nonserviceable hearing (Fig. 1) continued to decline in a relatively linear trajectory through the end of follow-up, suggesting that if patients were followed longer, the number with AAO-HNS Class A or B hearing would continue to decline. This is important because in most patients VSs are diagnosed in the 4th-5th decade of life, and these individuals are expected to live more than 20 years following SRS. Second, whereas previous studies have found cochlear dose to be an important contributor to hearing loss following SRS, our analysis did not find this to be significant. The patients presented in this study underwent SRS planning using earlier-generation software and only the modiolar point dose could be obtained to estimate the cochlear dose. Recently we found that the maximum cochlear dose, as determined by volumetric analysis, may be a more accurate prognostic tool than the modiolar point dose (JT Jacob, ML Carlson, TK Schiefer, et al., paper submitted to the CNS Annual Meeting, 2012). Finally, the argument can be made that the current cohort might do better if the most up-to-date dose delivery strategies were applied. Although this may be true, SRS technology and planning strategies continue to evolve, so we are in essence chasing a moving target. In the current series, all patients were treated with contemporary marginal dosing (12-13 Gy), highly conformal dose plans in which multiple small isocenters were used, and high-resolution MRI studies for targeting, all of which probably represent the most significant recent adaptations for reducing audiovestibular injury.
Conclusions
Hearing deterioration following SRS continues in a relatively linear trajectory well beyond initial treatment. Using modern dosing schemes, approximately one-fourth of patients will retain serviceable hearing a decade after SRS. Variables including pretreatment hearing capacity and tumor size are jointly statistically associated with time to nonserviceable hearing.
These data demonstrate the importance of long-term follow-up when reporting clinical outcomes following SRS. This may be particularly important with VS treatment because patients are expected to live decades beyond their diagnosis, and posttreatment audiovestibular deficits will only be compounded by age-related decline. Further studies performed using standardized outcome reporting and in-depth subgroup analysis with long-term follow-up are critical if we are to compare outcomes candidly following observation, microsurgical resection, and SRS.
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